EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudie

Randomized Phase II Trial of Amrubicin Plus Irinotecan Versus Cisplatin Plus Irinotecan in Chemo-naïve Patients With Extensive-Disease Small-Cell Lung Cancer: Results of the Japan Multinational Trial Organization (JMTO) LC 08-01

Hiroshige Yoshioka, Tadashi Ishida, Shinji Atagi, Akihiro Tamiya, Takashi Nishimura, Yasuo Iwamoto, Masashi Kanehara, Young Hak Kim, Yohei Korogi, Keisuke Tomii, Nobuyuki Katakami, Kiyoshi Komuta und 6 weitere

Clinical Lung Cancer · 2025

DOI: 10.1016/j.cllc.2024.09.004 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Hiroshige Yoshioka und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, Japan; Department of Respiratory Medicine, Kurashiki Central Hospital,…. Hauptthemen laut MEDLINE: Anthracyclines, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Irinotecan. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: We conducted a randomize phase II study to evaluate the efficacy and safety of topoisomerase II inhibitor amrubicin plus topoisomerase I inhibitor irinotecan (AI) compared with cisplatin plus irinotecan (PI) as first-line therapy in patients with extensive-disease (ED) small-cell lung cancer (SCLC). PATIENTS AND METHODS: Chemo-naïve patients with pathologically proven ED-SCLC (including limited disease (LD) SCLC with malignant effusion) were enrolled. Patients were randomized 1:1 to receive either AI (amrubicin 90mg/m2 on day 1 and irinotecan 50mg/m2 on days 1 and 8 of a 21-day cycle) or PI (cisplatin 60mg/m2 on day 1 and irinotecan 60mg/m2 on days 1, 8 and 15 of a 28-day cycle). The primary endpoint was overall survival proportion at 1 year. RESULTS: A total of 100 patients were randomly assigned to AI (n = 50) or to PI (n = 50). The 1-year overall survival proportions were 68.0% (95% confidence interval (CI): 56.2-82.2%) for AI and 59.2% (46.9-74.7%) for PI (1-sided P = .18). Median survival time was 14.8 months for AI and 13.5 months for PI with a hazard ratio (HR) of 0.618 (0.398-0.961, stratified log-rank test P = .031). Median progression-free survival time was 4.8 months for AI and 5.4 months for PI (stratified log-rank test, P = .54). Objective response rate was 70.0% (55.4-82.1%) for AI and 55.1% (40.2-69.3%) for PI (Fisher exact test, P = .15). There was no significant difference in hematological toxicity, whereas rates of vomiting, loss of appetite, diarrhea, and elevated serum creatinine are more frequent in PI. Interstitial lung disease (Grade 2 or 3) developed in 5 patients in AI and in 1 patient in PI. There was no treatment-related death. CONCLUSION: Although the study did not meet its primary endpoint, AI showed promising efficacy and good tolerability in chemo-naïve patients with ED-SCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnthracyclinesAntineoplastic Combined Chemotherapy ProtocolsCisplatinIrinotecanLung NeoplasmsSmall Cell Lung CarcinomaAdultAgedFemaleHumansMaleMiddle AgedJapanSurvival Rate

Stichwörter der Autor:innen

AmrubicinChemo-naïveExtensive-diseaseIrinotecanSmall-cell lung cancer

Substanzen

amrubicinAnthracyclinesCisplatinIrinotecan

Autor:innen und Institutionen

  • Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, Japan; Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan. Electronic address: hgyoshioka@gmail.com.
  • Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan.
  • Department of Thoracic Oncology, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Japan.
  • Department of Internal Medicine, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Japan.
  • Department of Respiratory Medicine, Kyoto Katsura Hospital, Kyoto, Japan.
  • Department of Medical Oncology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.

Zitieren

APA

Yoshioka, H., Ishida, T., Atagi, S., Tamiya, A., Nishimura, T., Iwamoto, Y., Kanehara, M., Kim, Y. H., Korogi, Y., Tomii, K., Katakami, N., Komuta, K., Nishikawa, M., Gemma, A., Yamaki, K., Kawahara, M., Miyakoshi, C., & Mio, T. (2025). Randomized Phase II Trial of Amrubicin Plus Irinotecan Versus Cisplatin Plus Irinotecan in Chemo-naïve Patients With Extensive-Disease Small-Cell Lung Cancer: Results of the Japan Multinational Trial Organization (JMTO) LC 08-01. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2024.09.004

Vancouver

Yoshioka H, Ishida T, Atagi S, Tamiya A, Nishimura T, Iwamoto Y, et al. Randomized Phase II Trial of Amrubicin Plus Irinotecan Versus Cisplatin Plus Irinotecan in Chemo-naïve Patients With Extensive-Disease Small-Cell Lung Cancer: Results of the Japan Multinational Trial Organization (JMTO) LC 08-01. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2024.09.004

BibTeX
@article{Yoshioka2025,
  author = {Yoshioka, Hiroshige and Ishida, Tadashi and Atagi, Shinji and Tamiya, Akihiro and Nishimura, Takashi and Iwamoto, Yasuo and Kanehara, Masashi and Kim, Young Hak and Korogi, Yohei and Tomii, Keisuke and Katakami, Nobuyuki and Komuta, Kiyoshi and Nishikawa, Masanori and Gemma, Akihiko and Yamaki, Kenichi and Kawahara, Masaaki and Miyakoshi, Chisato and Mio, Tadashi},
  title = {Randomized Phase II Trial of Amrubicin Plus Irinotecan Versus Cisplatin Plus Irinotecan in Chemo-naïve Patients With Extensive-Disease Small-Cell Lung Cancer: Results of the Japan Multinational Trial Organization (JMTO) LC 08-01},
  journal = {Clinical Lung Cancer},
  year = {2025},
  doi = {10.1016/j.cllc.2024.09.004}
}
Kostenlos starten →